For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Tafamidis meglumine represents a genuine change. These groundbreaking therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating t